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ABSTRACT 
Background: Typically, management of PCOS focuses on lifestyle changes (exercise and diet), 
aiming to alleviate symptoms, and lower the associated risk of type 2 diabetes and 
cardiovascular disease. Our objective was to analyse evidence on the effectiveness of exercise 
in the management of PCOS, when compared to (i) usual care; (ii) diet alone; and (iii) exercise 
combined with diet. Also, exercise combined with diet, compared to (i) control or usual care; 
and (ii) diet alone.  
Methods: Relevant databases were searched (June 2017) with no time limit for trial inclusion. 
Eligible trials employed a randomised, or quasi-randomised design to measure the chronic 
effects of exercise, or exercise and diet in women with PCOS.  
Results: Searches returned 2,390 articles; of those, 27 papers from 18 trials were included. 
Results are presented as mean difference (MD) and 95% confidence intervals (95% CI). 
Compared with control, exercise had a statistical effect on change from baseline fasting insulin 
(MD: -2.44 µIU/mL, 95% CIs: -4.24 to -0.64; very low-quality evidence), HOMA-IR (-0.57, -
0.99 to -0.14; very low-quality evidence), total cholesterol (-5.88 mg/dL, -9.92 to -1.83; low-
quality evidence), LDL cholesterol (-7.39 mg/dL, -9.83 to -4.95; low-quality evidence), and 
triglycerides (-4.78 mg/dL, -7.52 to -2.05; low quality evidence). Exercise also improved VO2 
max (3.84 ml/kg/min, 2.87 to 4.81), waist circumference (-2.62 cm, -4.13 to -1.11), and body 
fat percentage (-1.39%, -2.61 to -0.18) when compared with usual care. No effect was found 
for change value systolic/diastolic blood pressure, fasting glucose, HDL cholesterol (all low-
quality evidence), or waist-to-hip ratio. Many favourable change score findings were supported 
by post-intervention value analyses: fasting insulin (-2.11 µIU/mL, -3.49 to -0.73), total 
cholesterol (-6.66 mg/dL, -11.14 to -2.17), LDL cholesterol (-6.91 mg/dL, -12.02 to -1.80), and 
VO2 max (5.01 ml/kg/min, 3.48 to 6.54). Statistically lower BMI (-1.02 kg/m
2, -1.81 to -0.23) 
and resting heart rate (-3.26 beats/min -4.93 to -1.59) was also revealed in post-intervention 
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analysis. Subgroup analyses revealed the greatest improvements in overweight/obese 
participants, and more outcomes improved when interventions were supervised, aerobic in 
nature or of a shorter duration. Based on limited data, we found no differences for any outcome 
between the effects of exercise and diet combined, and diet alone. It was not possible to 
compare exercise vs diet or exercise and diet combined vs diet.  
Conclusion: Statistically beneficial effects of exercise were found for a range of metabolic, 
anthropometric and cardiorespiratory fitness related outcomes. However, caution should be 
adopted when interpreting these findings since many outcomes present modest effects and wide 
CIs, and statistical effects in many analyses are sensitive to the addition/removal of individual 
trials. Future work should focus on rigorously designed, well-reported trials that make 
comparisons involving both exercise and diet.  
Systematic review registration: This systematic review was prospectively registered on the 
Prospero International Prospective Register of Systematic Reviews (CRD42017062576). 
 
KEYWORDS 
Polycystic Ovary Syndrome; Exercise; Physical Activity; Diet; Cardiovascular risk; Insulin 
resistance; Cardiorespiratory fitness.  
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BACKGROUND 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-aged 
women, affecting 6-21% (depending on the applied diagnostic criteria) of this population 
worldwide [1-3]. PCOS is characterised by hyperandrogenism and/or chronic anovulation 
which can manifest with a range of symptoms (e.g. hirsutism, acne, oligomenorrhea, and 
infertility) [4] and is associated with increased risk of cardiometabolic disease, including 
hypertension, dyslipidaemia, insulin resistance (IR), and type 2 diabetes mellitus (T2DM) [5]. 
Moreover, PCOS is linked to increased psychological morbidity [e.g. increased risk of stress, 
depression, low self-esteem, poor body image, and reduced health-related quality of life 
(HRQoL)] [6, 7]. The exact PCOS aetiology is unknown, but increased adiposity is considered 
pivotal [8]. Indeed, almost 90% of women with PCOS are overweight or obese and even 
moderate weight loss (e.g. 5%) may result in clinically meaningful improvements in 
hyperandrogenism and menstrual regularity [9-13]. Also, women with PCOS often have more 
severe IR than weight-matched women without PCOS [14-15], while their increased 
susceptibility to obesity [16] may further exacerbate IR and the accompanying metabolic [17-
18] and reproductive [10, 19] dysfunctions. As such, women with PCOS exhibit increased risk 
of impaired glucose tolerance and T2DM regardless of weight and age [20].  
 
As there is currently no curative treatment for PCOS, management of overweight/obese women 
with PCOS focuses on weight loss through regular exercise and diet, aiming to alleviate its 
clinical manifestations and lower the related risk of T2DM and cardiovascular disease (CVD) 
[21]. Considering the benefits of exercise interventions in other IR populations independent of 
weight loss [22-24], incorporating moderate-intensity exercise in PCOS treatment may be 
particularly favourable. Existing evidence supports this; although most exercise trials in 
women with PCOS show little or no weight loss [5], exercise can have favourable effects on 
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IR, body fat distribution, and CVD risk in these patients [25]. As the number of studies 
investigating the effects of exercise and diet in PCOS is increasing, it is important to summarise 
this body of evidence in order to better inform clinical practice. Therefore, this systematic 
review aims to analyse the evidence on the effectiveness of exercise compared to (i) control or 
usual care; (ii) diet alone; and (iii) exercise combined with diet; as well as effectiveness of 
exercise combined with diet compared to (i) control or usual care; and (ii) diet alone. 
 
 
2. METHODS 
This systematic review was prospectively registered on the Prospero International Prospective 
Register of Systematic Reviews (CRD42017062576) and is reported based on the guidelines 
of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [26]. 
 
2.1 Search Methods for Identification of Studies 
Table 1 presents the eligibility criteria for inclusion in this systematic review. Only trials with 
women of reproductive age who had received a PCOS diagnosis were eligible for inclusion. 
Eligible trials employed a randomised, or quasi-randomised experimental (intervention) design 
to measure the chronic effects of exercise or exercise and diet in women with PCOS. We 
defined exercise as a potential disruption to homeostasis by muscle activity that is either 
exclusively, or in combination, concentric, eccentric or isometric [27]. Accordingly, we 
accepted all methods of exercise training, including continuous aerobic exercise (e.g., walking, 
jogging or cycling); high-intensity interval training; resistance training; flexibility training; and 
yoga, Tai Chi, and Pilates. Trials were eligible if they had a pre-post design that compared at 
least two conditions, using either within-subject cross-over design or between-subject 
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comparison to a control/alternative treatment group. Studies which included follow-up testing 
at least one month after completion of the intervention, were also included.  
 
Table 1. Eligibility criteria for including studies in this systematic review. 
 
The databases searched were CENTRAL (in the Cochrane Library), PubMed, CINAHL, 
SCOPUS, EMBASE (via Web of Science), SportDiscus (via EBSCOhost) and PsycINFO (via 
OvidSP). A search algorithm was developed for PubMed (Supplementary Table 1 in Additional 
File 1), which was then modified for each database searched.  
 
Searches were completed in June 2017 with no time limit specified for trial inclusion. Only 
fully published, peer-reviewed papers were included, whereas grey literature was not eligible. 
No language restrictions were placed on the search. 
 
Initial searches were completed by one reviewer (CK), duplicate records were removed before 
title and abstracts were screened independently by two reviewers (CK; IML). Subsequently, 
full-text eligibility screening was completed independently by two reviewers (CK; IML). Any 
disagreements on eligibility were resolved by discussion, whilst any unresolved disagreements 
by arbitration from a third reviewer (DRB). 
 
Where multiple publications for the same trial were retrieved, they were linked together, and 
the earliest paper of the trial was used as the primary reference. The earliest paper was used as 
the reference only, data were extracted from all papers with the most comprehensive available 
data included for each outcome. Data were extracted from eligible studies and a summary of 
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these findings are presented in Table 2. Trial data were combined in meta-analyses using 
Review Manager (RevMan 5.3.5, Copenhagen, Denmark). 
All trial outcomes were considered for inclusion following the search, but the primary 
outcomes were those linked to CVD risk (e.g., blood pressure, lipids, and glucose). Secondary 
outcomes were cardiorespiratory fitness (CRF), anthropometric measures, androgen levels, 
pro-inflammatory markers, and psychosocial outcomes. 
 
Table 2. Characteristics of studies included in this systematic review. 
   
2.2 Assessment of risk of bias in included studies 
The Cochrane Collaboration’s tool for assessing risk of bias was used; and six specific domains 
(sequence generation, allocation concealment, blinding, incomplete outcome data, selective 
outcome reporting, and any other sources of bias) were assessed. Two reviewers (CK; IA) 
assessed risk of bias, and a third reviewer (IML) arbitrated conflicts not due to assessor error. 
The Cochrane Handbook recommendations [28] were followed, and each bias parameter was 
graded as either high, low, or unclear risk. We judged studies with >20% of data missing as at 
a high risk of attrition bias. We considered studies with between-group baseline differences 
that may affect the outcome, less than 75% adherence in the intervention group, and 
contamination in the control group (i.e., control group participants engaged in exercise), as 
high risk of ‘other sources of bias’ [29]. In exercise trials, it is difficult to blind participants and 
researchers to the interventions resulting in a high risk of performance bias being made; this 
should not infer that the methodological quality of the trial is poor, but rather that the inevitable 
bias related to lack of blinding has been acknowledged by the reviewers. A risk of bias table is 
presented in Supplementary Table 2 and risk of bias summarised in the results (Figure 2; 
Supplementary Figure 1 in Additional File 2). 
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2.3 Strategy for data synthesis 
Where data from ≥2 trials were available, pooled intervention effect estimates and their 95% 
confidence intervals (CIs) are presented. Meta-analytical methods for involving continuous 
outcomes assume that data are normally distributed; hence, data were excluded from the meta-
analysis when they were clearly skewed, or results were reported with median and range values, 
and non-parametric tests used for analysis.  
 
Outcomes across each trial were presented as continuous data and, based on the Cochrane 
Handbook’s recommendations [30], the random-effects method for meta-analysis was utilised 
to combine data [31]. Mean ± standard deviation (SD) data for either change from baseline to 
post-intervention or immediately post-intervention values, were combined in a meta-analysis. 
The RevMan calculator was used to convert standard errors, CIs or t-values to SD where 
necessary. A priori the analysis was based on change from baseline scores as it removed a 
component of between-person variability [30]; immediately post-intervention analysis was also 
included so as to nullify the effect of selective reporting, but also to better indicate whether 
there was a treatment effect regardless of baseline values. Mean difference (MD) was used 
where trials reported the same outcome using the same scale. Where scales varied, units of 
measurement were converted to the most common measure [e.g., fasting insulin (FI) converted 
from pmol/L to µIU/mL]. If this was not possible, standardised mean difference (SMD) was 
used. Immediately post-intervention values were also assessed, and their data reported. If trials 
contained more than one eligible intervention arm [32-33], outcome data from both groups 
were combined using methods recommended by Deeks et al. [30]. If an included trial used a 
crossover design [34] then only data up to the point of crossover were used.   
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We used the Grades of Recommendation, Assessment, Development, and Evaluation 
(GRADE) approach [35] to assess the quality of the evidence for our primary outcomes: 
systolic and diastolic blood pressure, blood glucose, FI, homeostatic model assessment of 
insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. 
GRADEpro GDT software was used to develop the ‘Summary of findings’ table, and two 
review authors (IML & CK) graded the quality of the evidence for each outcome. We did not 
downgrade based on lack of blinding alone due to difficulties of blinding participants and 
exercise supervising personnel. We downgraded based on risk of bias only if a lack of blinding 
was accompanied by additional high risks of bias (e.g., selection bias and incomplete outcome 
reporting). 
 
2.4 Investigation of heterogeneity 
The I2 statistic was used to evaluate the heterogeneity of results for each outcome, across 
studies. Although not a measure of absolute heterogeneity, the I2 describes the percentage of 
variability in the point estimates that is due to heterogeneity rather than sampling error [30]. 
We interpreted heterogeneity as: 0-40% ‘might not be important’, 30-60% ‘may represent 
moderate heterogeneity’, 50-90% ‘may represent substantial heterogeneity’, and 75-90% 
‘considerable heterogeneity’ [30]. The importance of the observed I2 value depends on the 
magnitude and direction of effects, as well as the strength of evidence for heterogeneity. Visual 
inspection of forest plots was completed, and statistical heterogeneity assumed if there was 
little or no overlap of CIs for the results of individual studies. When evidence of at least 
substantial heterogeneity was present, its source was investigated by study population groups—
the trial that represented the largest outlier was removed from the analysis and the I2 was re-
evaluated. If heterogeneity was not reduced, it was also assessed in subgroup analyses. 
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2.5 Assessment of reporting biases 
To investigate publication bias, if there were ≥10 trials included in an analysis we used a funnel 
plot to explore the possibility of small study effects—a tendency for smaller studies to report 
larger beneficial effects. This was only completed for one outcome (BMI) because when there 
are fewer studies (<10), the power of tests is too low to distinguish chance from real asymmetry 
[30]. 
 
2.6 Subgroup analysis 
Where there were data from ≥2 studies, analyses of subgroups was conducted. Study 
characteristics analysed were: body mass index (BMI) upon study entry (BMI ≤24.9 kg/m2, 
25.0-29.9 kg/m2 or ≥30.0 kg/m2), intervention type (aerobic exercise, resistance training, or 
combination of the two), intervention duration (≤12 weeks or >12 weeks), and intervention 
delivery format (supervised, unsupervised, or mixed delivery). Outcome data were separated 
by subgroup and subtotal summary statistics were presented. The available data were 
insufficient to complete three of the sub-analyses (exercise intensity, combined treatments, and 
behaviour change components) outlined in the original protocol, but findings have been 
reported qualitatively where available. 
 
2.7 Sensitivity analysis  
Sensitivity analyses were completed on outcomes where an effect was observed to assess the 
effect of removing small sample size studies (n <30 total participants) and those with high 
overall bias risk. Due to the nature of the interventions, performance and detection bias were 
removed from the reviewers’ judgement. All studies exhibited at least one domain where risk 
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of bias was unclear, so only those with at least one domain where risk of bias was deemed to 
be high were removed. 
 
3. RESULTS 
3.1 Description of included studies 
3.1.1 Search Results  
In total, 2,390 articles were identified from the database searches; we were also sent one 
additional article after requesting further information from another author [108]. After 
removing duplicates, 1,908 articles were screened for eligibility based on title and abstract. A 
total of 87 full-text articles were retrieved for detailed eligibility evaluation, and 60 of these 
were excluded [36-95] with reasons detailed in Figure 1 and Supplementary Table 3.  
 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
flow diagram. 
 
Following exclusion, 27 met the inclusion criteria [32-34, 96-119]. However, these 
publications were based on 18 trials, since four trials had multiple publications, namely Stener-
Victorin et al. [111] four additional papers [100, 102, 112-113]; Thomson et al. [33] three 
additional publications [114-116]; Nybacka et al. [104] one additional publication [105]; and 
Sa et al. [107] one additional publication [108].  
One study was excluded from the meta-analysis [96] because data were reported as median and 
range values (attempts to contact the author were unsuccessful).  
3.1.2 Eligible studies design and attrition 
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Of the 18 included trials, 16 were randomised controlled clinical trials (RCTs), while one trial 
had a quasi-RCT [106] and another a randomised crossover [34] design.  
Twelve trials compared exercise to usual care or minimal intervention [32, 34, 96, 101, 103, 
107, 109-111, 117-119]. Three trials each compared combined exercise and diet with diet only 
[33, 97, 104], and exercise and diet combined with usual care [98-99, 106]. Only one trial [104] 
investigated exercise versus diet and exercise versus exercise and diet combined. The total 
number of participants included within the trials were 758 (exercise/intervention, n= 230; 
control, n= 257; combined treatment arms, n= 174; and diet alone, n= 54). In addition, 43 
participants were included in ineligible arms, i.e. pharmacological arm [99, 106, 110] and low-
frequency electroacupuncture [111]. 
Eight trials (44%) did not report any attrition [97-98, 101, 103, 106, 109-110, 118]. Where 
reported, attrition ranged from 6% [117] to 50% [33] with a median value of 19.5%; five trials 
(28%) reported attrition over 20% [32-33, 96, 99, 104]. Reasons for exercise dropouts included 
non-exercise related injury [32-34, 96, 119], pregnancy [32-34, 99, 119], time [33-34, 96], 
work/family commitments [32-33, 119], personal reasons [33, 104, 107, 111], medical grounds 
[96, 104, 111], and relocation [33]. Two trials excluded participants because adherence to 
intervention was <75% [117] or failure to comply with study requirements [33]. 
3.1.3 Participant characteristics of included studies 
Participant characteristics are presented in Table 2. Included trials used a range of criteria to 
diagnose PCOS as presented in Supplementary Table 4, with three trials [96, 98-99] using the 
NIH diagnostic criteria [120], whereas 14 [32-34, 97, 101, 103-104, 106-107, 109-111, 117-
118] used the Rotterdam consensus criteria [121]. One trial confirmed the PCOS diagnosis via 
participants’ general practitioner/specialist [119], but criteria used were unclear. No trials 
specified use of the AE-PCOS definition [122]. 
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Participants with T2DM, fasting hyperglycaemia, or glucose intolerance were explicitly 
excluded in nine trials (50%) [33-34, 96-97, 101, 109, 111, 117-118], and nine trials also 
excluded participants with any diagnosed CVD [33-34, 97-98, 109, 111, 117-119]. Another 
prerequisite in seven trials (39%) was the activity status of participants upon enrolment, namely 
a sedentary lifestyle and no recent participation in an exercise intervention had to be apparent 
[32-33, 96, 101, 103, 109, 119]. 
3.1.4 Intervention and comparison details 
Fourteen trials (74%) assessed the effectiveness of an exercise only intervention and six trials 
(32%) assessed a combined exercise and dietary intervention. Moreover, 14 trials (74%) 
included intervention arms consisting of aerobic exercise only, and a further three (16%) 
combined aerobic exercise with resistance training [33, 97, 117]. Of those incorporating 
aerobic exercise (n= 17, 94%), 11 trials (61%) specified either walking, brisk walking or 
jogging [32-34, 96-98, 103-104, 107, 109, 111] and seven (39%) incorporated static cycling 
either on its own or as part of a wider intervention [32, 34, 96-97, 101, 111, 118]. A trial each 
incorporated elliptical training [96], step training [117], and [104] swimming. Five trials (28%) 
[32, 96-97, 104, 111] allowed participants to self-select modality from those listed above, 
whereas two trials [99, 106] allowed participants to self-select a modality but without stating 
the choices. Three trials (16%) had arms that were resistance training only [32, 110, 119]. 
However, in one trial the type of exercise was unclear [106]. 
The modal training session frequency was three per week in 10 trials (56%) [32-33, 97, 103, 
107, 109-111, 117-118]. Five sessions per week were prescribed in three (17%) trials [33, 98, 
101], whereas in another trial [119] four sessions per week were set. Of the remaining four 
trials, one specified a weekly physical activity (PA) time target of 150 minutes per week [99], 
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one trial set an exercise dose of 14 kcal/kg/week [96], and two did not specify training 
frequency or volume [104, 106].  
Eight trials (44%) set aerobic exercise intensity using a percentage of the maximum heart rate 
(HRmax) [32-34, 97, 103, 107, 109, 117] or maximal oxygen uptake (VO2 max) [96, 101, 118]. 
One trial specified that heart rate (HR) was set at ≥120 beats/min [111]. Three trials using 
resistance training prescribed intensity based on a percentage of 1-repetition maximum (either 
40-60% [110] or 50-75% [32-33]). One resistance training intervention set intensity using a 
rate of perceived exertion of 5-6 out of 10 [117]. Six trials did not specify the intensity of the 
intervention [97-99, 104, 106, 119]. Four trials increased the intensity as the intervention 
progressed [33, 103, 10-110]. 
Eleven trials (61%) prescribed session durations of one hour or less (≤30 minutes [32, 34, 103, 
109, 118], >30-60 minutes [96, 101, 107, 111, 119] or 20-30 to 45 minutes [33]). Only one trial 
consisted of training sessions of >60 minutes [97]. Hoeger and colleagues [99] specified 150 
minutes as a weekly target, whereas another trial used a target distance of 10 miles per week 
[98]. Four trials did not specify timings for their intervention [104, 106, 110, 11]. 
In ten trials (56%), participants were fully supervised in all exercise sessions [34, 97, 101, 103-
104, 107, 109-110, 117-118], while two (11%) used a mixed approach with some supervised 
sessions [32, 119], and one (6%) was unsupervised with support provided weekly by telephone 
[111]. The remaining five trials (26%) did not report supervision status.  
Six trials (33%) incorporated a dietary component. Five of these trials (28%) specified either a 
daily caloric target [33, 98], a reduced caloric intake [104, 106], or an individualised caloric 
deficit [99]. The other of these trials [97] used weekly nutritional counselling sessions to 
educate participants on a range of nutritional topics. 
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Thirteen trials (72%) had a control arm (Table 2) [32, 34, 96. 98, 101, 103, 107, 109-111, 117-
119]. Three of these trials offered participants the intervention [34, 98] or a one-month gym 
membership [32] upon completion of the trial (wait-list control). Three of the remaining trials 
(17%) used a diet only arm as their comparison group [33, 97, 104], one trial used a placebo 
[99], and another used metformin treatment only [106]. 
3.1.5 Characteristics of the outcome measures 
All studies assessed participants at baseline and immediately post-intervention (Table 2), whilst 
two trials incorporated an additional midway assessment [33, 99], one trial added a follow-up 
assessment 16 weeks post-intervention [111], and another trial assessed at baseline, crossover 
and immediately post-intervention [34]. No post-intervention follow-up analysis was possible 
due to lack of studies. 
Seven trials (39%) stated the sample size calculation methods [32, 96, 107, 109-111, 118], 
although only five (28%) of those reported the outcome upon which their calculations were 
based [32, 96, 104, 107, 111]. The primary outcomes (used in sample size calculation) were: 
HOMA-IR [32], VO2 peak [107], total testosterone [111], insulin sensitivity [96], and BMI 
[104]. Only three trials stated recruitment targets [32, 107, 111]; all three trials achieved their 
sample size calculated target. The outcomes included in each trial are provided in Table 2.  
 
3.2 Assessment of risk of bias in included studies 
The authors’ risk of bias judgements are presented in the Risk of Bias Graph (Figure 2), while 
further details are included in Supplementary Figure 1 and Supplementary Table 2. 
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Figure 2. Review of authors’ judgement of each methodological quality item from the 
Cochrane Risk of Bias tool, presented as a percentage across all 18 included studies. 
 
Only four trials (22%) were judged to have a low risk of selection bias, using appropriate 
methods to generate their randomisation sequence and conceal allocation [32, 96, 117, 119]. 
One trial was judged to be at high risk of selection bias [107] because five participants were 
allocated to the control group based upon their geographical location. The remaining trials were 
judged to have an unclear risk of selection bias due to insufficient reporting of sequence 
generation or allocation concealment methods. Due to the nature of the interventions, all trials 
were judged to be at a high risk for performance bias. Only one trial had a low risk for detection 
bias [118]; the remaining trials were judged to be at a high risk of this bias due to not stating 
whether outcome assessors were blinded to participant allocation. One trial [32] used an 
independent, and blinded, assessor for evaluation of only one outcome (flow mediated 
dilation). 
Eight trials (44%) were judged to be high risk for attrition bias because participant withdrawal 
rates were >20% [33, 96, 99, 104, 111], incomplete data due to lab error [97], inappropriate 
handling of missing data (i.e., last observation carried forward) [119], and only a subset of 
participants completing hyperinsulinaemic-euglycemic clamp testing [101]. A prospective 
protocol document, or trial registration was available only for three trials, thus making it 
difficult to judge whether all intended outcomes had been reported. The remaining 14 trials 
(78%) were judged to have an unclear risk of reporting bias, and one trial [107] was judged to 
be high risk due to incomplete reporting of results.  
Eleven trials (61%) had low risk of bias based upon statistical similarities between groups at 
baseline [32, 34, 97-99, 101, 104, 107, 111, 114, 117]. Of the high-risk trials, one [119] had 
participants in the intervention group with less favourable adiposity and body composition 
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versus control. Similarly, another trial [96] had an older exercise group that was less 
hyperandrogenic and hirsute, and had lower levels of CRF and higher BMI, plasma lipids, and 
IR levels compared with controls. 
Adherence was reported in seven trials (39%) [32, 34, 96, 111, 117-119], with a median of 
90% adherence, ranging from 67% [34] to 103% [111]. Two of the trials (11%) reported 
intervention adherence below the 75% threshold outlined in the methods [34, 119]. Five trials 
(28%) were judged to have a low risk of adherence bias (adherence ≥75%) [32, 96, 111, 117-
118]. Finally, most trials (n= 14, 78%) were deemed to have unclear risk of contamination bias 
due to lack of reporting. Only one trial [118] had a low risk of contamination bias as the control 
group did not increase PA >4 MET/hr/wk [123], whereas three trials (17%) had a high risk of 
contamination as it was reported that comparison groups had either engaged in treatment [34, 
111], or control groups had not received their allocated intervention [107]. 
 
3.3 Effects of interventions: Exercise versus Control 
Due to data availability, a meta-analysis was possible only for three comparisons: 1) exercise 
versus control; 2) exercise and diet combined versus control; and 3) exercise and diet combined 
versus diet only. 
Eleven trials were included in the exercise versus control meta-analysis as presented in Table 
3 [32, 34, 101, 103, 107, 109-111, 117-119].  
 
Table 3. Effect estimates and heterogeneity for change from baseline to post-intervention 
scores and immediately post-intervention values, for all outcomes analysed in the exercise 
versus control comparison 
 
Table 4. Summary of findings for Primary Outcomes: exercise versus control. 
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Primary outcomes 
3.3.1 Blood Pressure 
Four eligible trials (158 participants) assessed changes in blood pressure. We found no 
significant effect of exercise on systolic blood pressure (SBP) or diastolic blood pressure (DBP) 
for either change scores or post-intervention values compared with control (Table 3). We rated 
the result of both SBP and DBP as low-quality evidence due to imprecision (small number of 
participants, and a null and appreciable effect were included in the 95% CI for the MD), and 
high or unclear risk of selection bias, detection bias, reporting bias, attrition bias, and 
contamination (See Table 4; Summary of findings for primary outcomes). 
In subgroup analyses (Supplementary Table 5), we only found effects of supervised 
interventions (MD: -4.42 mmHg, 95% CI: -8.32 to -0.51; 3 trials, 147 participants, I2= 31%) 
on the SBP change compared with control. No effects were found in subgroup analysis of SBP 
post-intervention values or in any DBP subgroup analysis. 
3.3.2 Fasting Blood Glucose  
Based on data from nine trials (263 participants), we found no effect of exercise on fasting 
blood glucose (FBG) change or absolute post-intervention values compared with control (Table 
3). There was also no effect of exercise for any of the subgroup analyses presented in 
Supplementary Table 5. We rated the result as low-quality evidence due to an unclear or high-
risk of selection, detection, and reporting bias, contamination, low adherence, small number of 
participants, and a null or negligible effect and appreciable benefit included in the confidence 
interval for the mean difference (Table 4). 
3.3.3 Fasting Insulin 
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Meta-analysis of nine trials (263 participants) revealed a favourable effect of exercise on the 
change of FI values from baseline compared with control (MD: -2.44 µIU/mL, 95% CI: -4.24 
to -0.64; Figure 3), but with evidence of considerable heterogeneity (I2= 91%). Similarly, 
statistically significant lowering effects of exercise versus control were found for FI post-
intervention values (MD: -2.11 µIU/mL, 95% CI: -3.49 to -0.73; 8 trials, 238 participants, I2= 
40%). Applying GRADE, we rated the result as very low-quality (Table 4) evidence due to 
unclear or high risk randomisation or allocation procedures, lack of blinding, high rate of 
incomplete outcome data, unclear reporting of outcomes and contamination, low adherence, 
considerable heterogeneity in the effects in individual studies, small number of participants, 
and wide confidence interval for the mean difference.  
 
Figure 3. Forest plot of comparison: Exercise vs. Control, outcome: fasting insulin plasma 
levels (µIU/mL). 
 
In sensitivity analyses, the observed effect of exercise on FI change from baseline remained 
when only trials with larger sample sizes (n ≥30 total participants) (MD: -1.09 µIU/mL, 95% 
CI: -1.64 to -0.53; 2 trials, 120 participants, I2= 7%) and studies with a low risk of bias (MD: -
3.18 µIU/mL, 95% CI: -5.63 to -0.74; 187 participants, 5 trials, I2= 95%) were included. 
Likewise, post-intervention FI effects remained when small trials (MD: -1.73 µIU/mL, 95% 
CI: -3.00 to -0.47; 2 trials, 160 participants, I2= 5%) and trials with a high risk of bias (MD: -
2.10 µIU/mL, 95% CI: -3.04 to -1.17; 5 trials, 187 participants, I2= 0%) were removed. 
To identify the potential source of heterogeneity in the FI change analysis, when the greatest 
outlier [110] was removed, the I2 statistic was reduced to a level that may not be important 
(18%) and the effect was maintained (MD: -1.54 µIU/mL, 95% CI: -2.36 to -0.71). The results 
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of the removed trial may have varied due to the mode of exercise used (resistance training) or 
the use of a placebo.  
A statistical effect of exercise versus control on FI was shown in multiple subgroups 
(Supplementary Table 5). We found a change in FI from baseline to post-intervention in studies 
with participants who were overweight (BMI: 25-29.9 kg/m2, MD: -3.25 µIU/mL, 95% CI: -
5.27 to -1.22; 5 trials, 168 participants, I2= 75%); interventions that were aerobic exercise-
based (MD: -2.22 µIU/mL, 95% CI: -3.57 to -0.86; 6 trials, 192 participants, I2= 10%); ≤12 
weeks duration (MD: -2.92 µIU/mL, 95% CI: -4.91 to -0.93; 7 trials, 225 participants, I2= 
93%); and supervised and combined supervised and unsupervised (MD: -2.54 µIU/mL, 95% 
CI: -4.82 to -0.26; 6 trials, 214 participants, I2= 94%, and MD: -3.08 µIU/mL, 95% CI: -5.63 
to -0.53; 2 trials, 38 participants, I2= 17%, respectively). 
Compared with control, favourable effects of exercise on FI post-intervention values were 
found for participants who were overweight (MD: -2.27 µIU/mL, 95% CI: -3.24 to -1.31; 5 
trials, 168 participants, I2= 0%); interventions that were aerobic exercise-based (MD: -2.48 
µIU/mL, 95% CI: -3.92 to -1.04; 5 trials, 167 participants, I2= 10%); ≤12 weeks duration (MD: 
-1.80 µIU/mL, 95% CI: -3.18 to -0.42; 6 trials, 200 participants, I2= 32%); and supervised 
(MD: -2.39 µIU/mL, 95% CI: -3.62 to -1.17; 5 trials, 189 participants, I2= 30%). 
3.3.4 HOMA-IR  
Greater reductions in HOMA-IR change scores were evident for exercise versus control (MD: 
-0.57, 95% CI: -0.99 to -0.14; 8 trials, 173 participants, I2= 87%; Table 3; Figure 4), but the 
comparison of post-intervention HOMA-IR values did not reveal a significant exercise effect. 
In a sensitivity analysis including only trials at a low risk of bias, the effect of exercise was 
maintained (MD: -0.81, 95% CI: -1.40 to -0.21; 97 participants, 4 trials, I2= 77%) for HOMA-
IR changes. Only one trial had a sample size of ≥30 participants [117], so a corresponding 
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sensitivity analysis was not possible. We rated the result as very low-quality evidence due to 
unclear or high risk of selection, detection, attrition, and reporting bias, contamination, low 
adherence, considerable heterogeneity with minimal or no overlap of confidence intervals, 
small number of participants, and a null or negligible effect and appreciable benefit included 
in the confidence interval for the mean difference (Table 4).  
 
Figure 4. Forest plot of comparison: Exercise vs. Control, outcome: Homeostatic Model 
Assessment for Insulin Resistance (HOMA-IR). 
 
In the investigation of heterogeneity, removing the most extreme value [32] had a negligible 
effect on the I2 (89%), but a small effect was maintained (MD: -0.50, 95% CI: -0.96 to -0.05). 
Similarly, the I2 statistic was still representative of at least substantial heterogeneity in sub-
analyses. The lowest reported value (I2= 60%) was in the aerobic exercise intervention 
subgroup.  
Subgroup analyses revealed statistical effects on HOMA-IR change from baseline for aerobic 
exercise interventions (MD: -0.73, 95% CI: -1.24 to -0.21; 5 trials, 102 participants, I2= 60%); 
≤12 weeks duration (MD: -0.69, 95% CI: -1.13 to -0.26; 6 trials, 135 participants, I2= 89%); 
and supervised delivery (MD: -0.80, 95% CI: -1.19 to -0.42; 5 trials, 124 participants, I2= 76%); 
and for participants in the overweight subgroup (MD: -0.83, 95% CI: -1.39 to -0.26; 4 trials, 
78 participants, I2= 75%). Post-intervention subgroup analysis revealed no effects 
(Supplementary Table 5).  
3.3.5 Circulating lipids 
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Seven trials (225 participants) were included in the analysis of all lipid-related outcomes (TC, 
LDL-C and HDL-C, and triglycerides; Figure 5; Table 3). A statistically significant effect of 
exercise versus control was observed for TC change scores (MD: -5.88 mg/dL, 95% CI: -9.92 
to -1.83; I2= 35%), LDL-C (MD: -7.39 mg/dL, 95% CI: -9.83 to -4.95; I2= 0%), and 
triglycerides (MD: -4.78 mg/dL, 95% CI: -7.52 to -2.05; I2= 3%), but not for HDL-C (Table 
3). Post-intervention values analysis of lipid-related outcomes revealed an effect on TC (MD: 
-6.35 mg/dL, 95% CI: -10.76 to -1.95; I2= 0%) and LDL-C (MD: -6.68 mg/dL, 95% CI: -11.66 
to -1.70; I2= 0%) (Table 3). We rated these results as low-quality evidence (Table 4) due to 
high or unclear risk of selection bias, detection bias, reporting bias, contamination, and 
imprecision due to small number of participants and wide confidence intervals in the included 
trials. 
 
Figure 5. Forest plot of comparison: Exercise vs. Control, change from baseline to immediately 
post-intervention analysis of outcomes related to lipid profile (mg/dL). 
 
In sensitivity analyses, the favourable effects of exercise versus control on TC, LDL-C, and 
triglycerides change scores were maintained in studies with a low risk of bias (MD: -5.94 
md/dL, 95% CI: -10.32 to -1.55; 5 trials, 187 participants, I2= 40%; MD: -6.60 mg/dL, 95% 
CI: -9.88 to -3.32; 5 trials, 187 participants, I2= 14%; and MD: -5.97 mg/dL, 95% CI: -10.91 
to -1.03; 5 trials, 187 participants, I2 = 33%, respectively), and in larger trials (MD: -3.74 
mg/dL, 95% CI: -6.13 to -1.35; 120 participants, 2 trials, I2= 0%; MD: -8.58, 95% CI: -11.44 
to -5.71; 120 participants, 2 trials, I2= 0%; and MD: -3.62 mg/dL, 95% CI: -6.22 to -1.02; 120 
participants, 2 trials, I2= 0%, respectively). Sensitivity analyses for LDL-C post-intervention 
values showed a retained effect when trials with a high risk of bias were excluded (MD: -8.64 
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mg/dL, 95% CI: -16.30 to -0.98; 5 trials, 187 participants, I2= 22%), but not when smaller trials 
were removed. 
Subgroup analyses of TC change (Supplementary Table 6) revealed statistical effects for 
interventions that were ≤12 weeks duration (MD: -5.94 mg/dL, 95% CI: -10.32 to -1.55; 5 
trials, 187 participants, I2= 37%) or supervised (MD: -7.25 mg/dL, 95% CI: -11.92 to -2.58; 5 
trials, 189 participants, I2= 48%). There was also an effect in subgroup analysis for change 
from baseline (MD: -6.68 mg/dL, 95% CI: -13.00 to -0.35; 5 trials, 167 participants, I2= 39%) 
and post-intervention TC values (MD: -6.90 mg/dL, 95% CI: -11.90 to -1.90; 5 trials, 167 
participants, I2= 0%) in aerobic exercise interventions. Subgroup analysis of post-intervention 
TC also revealed an effect when interventions >12 weeks (MD: -9.92 mg/dL, 95% CI: -17.81 
to -2.04; 2 trials, 38 participants, I2= 0%) or were supervised (MD: -6.76 mg/dL, 95% CI: -
11.27 to -2.26; 5 trials, 189 participants, I2= 0%).  
In subgroup analyses for LDL-C change from baseline, a statistically favourable exercise effect 
was found in trials consisting of interventions ≤12 weeks duration (MD: -6.60 mg/dL, 95% CI: 
-9.88 to -3.32; 5 trials, 187 participants, I2= 13%), or supervised (MD: -6.70 mg/dL, 95% CI: -
10.29 to -3.12; 5 trials, 189 participants, I2= 23%). Subgroup analysis for LDL-C post-
intervention values revealed statistical effects in participants with BMI of 25-29.9 kg/m2 (MD: 
-9.54 mg/dL, 95% CI: -18.71 to -0.36; 5 trials, 168 participants, I2= 22%), and interventions of 
≤12 weeks duration (MD: -8.64 mg/dL, 95% CI: -16.30 to -0.98; 5 trials, 187 participants, I2= 
22%), supervised (MD: -7.58 mg/dL, 95% CI: -13.73 to -1.43; 5 trials, 187 participants, I2= 
24%) or aerobic (MD: -5.87 mg/dL, 95% CI: -11.68 to -0.07; 5 trials, 167 participants, I2= 0%; 
Supplementary Table 6).  
For HDL-C, only subgroup analyses of resistance training interventions showed a negative 
effect on change from baseline scores (MD: -2.19 mg/dL, 95% CI: -4.21 to -0.18; 2 trials, 37 
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participants, I2= 0%), and a positive effect on post-intervention values (MD: 7.29 mg/dL, 95% 
CI: 1.11 to 13.46; 2 trials, 37 participants, I2= 17%; Supplementary Table 6). No effects of 
exercise were found in other HDL-C subgroup analyses. 
Compared with control, exercise had a favourable effect on triglyceride values in the following 
subgroups: BMI: 25-29.9 kg/m2 (MD: -8.17 mg/dL, 95% CI: -14.44 to -1.89; 5 trials, 167 
participants, I2= 13%); aerobic exercise interventions (MD: -6.80 mg/dL, 95% CI: -13.12 to -
0.48; 5 trials, 167 participants, I2= 5%); ≤12 weeks duration (MD: -6.06 mg/dL, 95% CI: -
10.82 to -1.31; 5 trials, 187 participants, I2= 30%); and supervised interventions (MD: -5.91 
mg/dL, 95% CI: -10.75 to -1.06; 5 trials, 189 participants, I2= 29%; Supplementary Table 6). 
Analysis of triglyceride post-intervention values revealed an effect of exercise in trials >12 
weeks only (MD: -13.85 mg/dL, 95% CI: -26.33 to -1.36; 2 trials, 38 participants, I2= 0%).  
 
Secondary outcomes 
3.3.6 Maximal or peak oxygen uptake 
A large statistical effect of exercise versus control was found for both change from baseline 
and post-intervention VO2 max/peak values (SMD: 1.43, 95% CI: 0.84 to 2.03; 259 
participants, 7 trials, I2= 74%, and SMD: 1.19, 95% CI: 0.40 to 1.99; I2= 83%, respectively; 
Figure 6). With the inclusion of only studies that reported relative VO2 max/peak values (i.e. 
expressed as ml/kg/min), the effect of exercise was maintained in both change scores and post-
intervention values (MD: 3.84 ml/kg/min, 95% CI: 2.87 to 4.81; 6 trials, 229 participants, I2= 
17%, and MD: 5.01 ml/kg/min, 95% CI: 3.48 to 6.54; 5 trials, 184 participants, I2= 42%, 
respectively).  
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Figure 6. Forest plot of comparison: Exercise vs. Control, Standardised Mean Difference; 
outcome: VO2 max/peak. 
 
For the SMD VO2 max/peak change sensitivity analysis, an effect remained when small trials 
(SMD: 1.21, 95% CI: 0.29 to 2.12; 3 trials, 165 participants, I2= 83%) and those with a high 
risk of bias (SMD: 1.63, 95% CI: 0.78 to 2.48; 5 trials, 187 participants, I2= 80%) were 
removed. SMD was also used to complete post-intervention sensitivity analysis for sample 
size; 2 trials (120 participants) [116-117] were included, but the effect was lost. However, it 
remained when trials with a high risk of bias were removed (SMD: 1.16, 95% CI: 0.21 to 2.12; 
5 trials, 187 participants, I2= 87%). 
When we considered only relative VO2 max/peak change scores, the effect of exercise was 
maintained when removing small studies (MD: 1.21 ml/kg/min, 95% CI: 0.29 to 2.12, 165 
participants, 3 trials, I2= 83%) and studies with a high risk of bias (MD: 3.35 ml/kg/min, 95% 
CI: 2.59 to 4.10; 157 participants, 4 trials, I2= 0%). All trials in the post-intervention relative 
VO2 max/peak analysis were considered low risk of bias, so this sensitivity analysis was not 
possible.  
For ease of interpretation, we performed subgroup analyses on the relative VO2 max/peak data. 
Subgroup analysis of the change from baseline relative VO2 max/peak values revealed 
statistical improvements with aerobic exercise, any intervention duration and for participants 
with a BMI of 25-29.9 kg/m2. The post-intervention pooled analysis showed an effect of 
exercise on relative VO2 max/peak in four subgroups: participants with a BMI of 25-29.9 
kg/m2, aerobic exercise interventions, ≤12 weeks, and supervised (Supplementary Table 7).  
In one trial reporting data from a post-intervention 16-week follow-up [111], a 12% increase 
in VO2 max (4.11 ± 5.20 ml/kg/min; p = .001) from baseline was still evident in the exercise 
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group. The corresponding change for control (7%) was not statistically significant, and there 
were no significant differences between groups.  
3.3.7 Resting heart rate  
A pooled analysis of four trials (156 participants) indicated no effect of exercise on the change 
scores of resting heart rate (RHR) values (Table 3). However, in these trials, RHR post-
intervention values were statistically lower in the exercise interventions versus control (MD: -
3.26 beats/min, 95% CI: -4.93 to -1.59; I2= 0%). When post-intervention sensitivity analyses 
were completed, this effect was still evident in larger trials (MD: -3.18 beats/min, 95% CI: -
5.59 to -0.77, 3 trials, 145 participants, I2= 16%), and those with a low risk of bias (MD: -3.53 
beats/min, 95% CI: -5.28 to -1.78; 2 trials, 120 participants, I2= 0%). 
In subgroup analyses, there were statistical effects of exercise compared with control on both 
RHR change from baseline and post-intervention values in interventions that were aerobic 
exercise-based (Supplementary Figure 3), and those that were supervised. Post-intervention 
subgroup analysis also revealed effects in interventions of ≤12 weeks and when participants 
had a BMI 25-29.9 kg/m2 at study entry (Supplementary Table 7).  
3.3.8 Body mass and Body Mass Index  
We found a statistical effect of exercise on BMI post-intervention values (MD: -1.02 kg/m2, 
95% CI: -1.81 to -0.23; 10 trials, 272 participants, I2= 0%) compared with control (Table 3). 
When trials with a high risk of bias were removed from the sensitivity analysis for BMI post-
intervention values, an effect remained (MD: -0.95 kg/m2, 95% CI: -1.78 to -0.12; 6 trials, 207 
participants, I2= 0%), but not when small trials were removed.  
Subgroup analysis revealed a statistical reduction in BMI change scores with exercise in studies 
consisting of participants with BMI ≥30 kg/m2. Analysis of BMI change from baseline also 
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revealed a statistical decrease with aerobic exercise interventions, but a statistical increase with 
resistance training interventions (Supplementary Table 7).  
Post-intervention subgroup analysis revealed statistical reductions in BMI with interventions 
that were aerobic exercise-based, supervised, ≤12 weeks, and also in participants with a BMI 
of 25-29.9 kg/m2 (Supplementary Table 7). 
The meta-analysis revealed no effect of exercise versus control on body mass change from 
baseline or post-intervention values (Table 3). However, we found statistical effects of exercise 
versus control on change in body mass from baseline to post-intervention for studies involving 
participants with BMI ≥30 kg/m2. No other subgroup analyses indicated such an effect 
(Supplementary Table 7). 
Follow-up reporting (16 weeks post-intervention) of BMI from one trial [111] showed no 
statistically significant within-group changes or between-group differences in either exercise 
or control arms. The authors [111] also reported similar findings immediately post-
intervention. 
3.3.9 Waist and hip circumference and waist-to-hip ratio 
Analysis of waist circumference (WC) change scores, but not post-intervention values, 
revealed a statistically significant beneficial effect of exercise compared with controls (MD: -
2.62 cm, 95% CI: -4.13 to -1.11; 7 trials, 221 participants, I2= 53%; Table 3). The favourable 
effect of exercise on WC change remained when trials with a low risk of bias (MD: -1.51 cm, 
95% CI: -2.26 to -0.76; 167 participants, 4 trials, I2= 0%) and larger sample sizes (MD: -1.48 
cm, 95% CI: -2.26 to -0.71; 120 participants, 2 trials, I2= 0%) were analysed separately. When 
the largest outlier [107] was removed from this analysis, the I2 was reduced to 0% and an effect 
remained (MD: -1.68 cm, 95% CI: -2.38 to -0.99). 
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In subgroup analyses for WC change, exercise had a statistical effect in studies with 
participants with BMI of 25-29.9 kg/m2 and ≥30 kg/m2, ≤12 week’s duration, aerobic and 
resistance-based interventions, and supervised exercise (Supplementary Table 7). Subgroup 
analysis revealed that post-intervention WC values were statistically lower in exercise 
interventions with participants with BMI 25-29.9 kg/m2, aerobic exercise, and supervision 
(Supplementary Table 7). 
Data from two trials [111, 118] were pooled in the analysis of waist-to-hip ratio (WHR); there 
was no effect in either change from baseline or post-intervention values analyses.  
3.3.10 Body composition 
The pooled MD for body fat percentage change from baseline was statistically significant (MD: 
-1.39%, 95% CI: -2.61 to -0.18; 3 trials, 60 participants, I2= 30%), but not for post-intervention 
values (Table 3). When trials deemed to have a high risk of bias were removed, this statistical 
effect disappeared. Sensitivity analysis by study size could not be performed for the exercise 
effect on body fat percentage due to a lack of sufficiently large studies. Moreover, we found 
no effect of exercise versus control on change from baseline or post-intervention analyses for 
fat mass and fat-free mass (Table 3). 
A statistical effect was found for exercise on body fat percentage change in interventions ≤12 
weeks, but this analysis included the same trials as the main analysis. No other statistical effects 
were found across any of the other subgroup analyses on body fat percentage change 
(Supplementary Table 7). However, body fat percentage was statistically lower post-
intervention in exercise interventions that included participants with BMI of 25-29.9 kg/m2, 
and aerobic exercise (Supplementary Table 7). No effect was evident in the subgroup analysis 
for fat mass or fat-free mass. 
3.3.11 Androgenic, hormonal, and inflammatory markers 
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In pooled analyses of change from baseline or post-intervention values, exercise had no 
beneficial effect on any of the androgenic/hormonal and inflammatory biomarkers/variables 
[i.e., testosterone, free testosterone, free androgen index (FAI), sex hormone binding globulin 
(SHBG), Ferriman-Gallwey scores, oestradiol, luteinising hormone (LH), follicle stimulating 
hormone (FSH), LH/FSH ratio, progesterone, prolactin, high-sensitivity C-reactive protein, 
anti-Mullerian hormone (AMH), or adiponectin] when compared with control (Table 3). 
Similarly, there were no effects in any subgroup analysis for these outcomes (Supplementary 
Table 8).  
3.3.12 Psychosocial Outcomes 
In two trials (57 participants) that assessed psychosocial outcomes using the PCOS-Q, we 
found no effect of exercise on any PCOS-Q domain compared with control. Three trials (84 
participants) used the SF-36. Data only allowed for change from baseline analysis and no sub-
analysis was possible. For SF-36 domains, a favourable effect of exercise versus control was 
found for physical functioning (MD: 11.81, 95% CI: 2.36 to 21.25; I2= 74%), general health 
(MD: 10.05, 95% CI: 3.89 to 16.20; I2= 0%), social functioning (MD: 11.75, 95% CI: 2.56 to 
20.95; I2= 6%), and mental health (MD: 11.70, 95% CI: 1.27 to 22.13; I2= 47%) domains 
(Supplementary Figure 5).  
There were insufficient data to complete sensitivity analyses; however, all three trials [107, 
111, 119] were judged to have a high risk of bias in at least one domain, and only one trial had 
a sample size ≥30. Heterogeneity was investigated in the physical functioning domain; the 
largest outlier was removed [107] and the I2 was reduced to 33%, whilst an effect was 
maintained (MD: 7.23, 95% CI: 1.66 to 12.80). The same trial was removed in the general 
health analysis, resulting in a reduction in I2 to 0%, and a preserved effect (MD: 7.97, 95% CI: 
1.07 to 4.88). When the greatest outliers were removed from the social functioning [119] and 
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mental health [111] domains, both I2 values were reduced to 0%, but the effect only remained 
in the mental health domain (MD: 17.84, 95% CI: 7.33 to 28.36).  
3.3.13 Additional Outcomes  
Six trials [32, 107, 111, 117-119] also reported a range of additional outcomes; the key findings 
from these are presented in Supplementary Table 9. 
 
3.4 Effects of interventions: Exercise and Diet versus Control 
Three trials compared exercise and diet combined versus control. Only one of these trials used 
a control group that was described as no treatment [98]. The other two [99, 106] compared 
exercise, diet and metformin (or placebo) to metformin only groups. As pharmacological 
intervention was present in each included treatment arm, we assumed that any variation 
between groups would result from exercise and dietary components.  
Due to insufficient data it was only possible to include two outcomes in the meta-analysis. 
Meta-analysis of the two trials (68 participants) reporting change from baseline to post-
intervention WHR values revealed a small but statistically significant effect in favour of 
exercise and diet (MD: -0.02, 95% CI: -0.03 to -0.01; I2= 0%; Supplementary Figure 6). The 
effect was not replicated in the post-intervention value analysis. 
We found no effect of exercise and diet combined versus control on the change from baseline 
to post-intervention SHBG concentrations (Supplementary Figure 7). There were insufficient 
data to complete analysis of post-intervention values or subgroups. Individual outcomes were 
also reported by each of these trials, which are summarised in Supplementary Table 10.  
 
3.5 Effects of interventions: Exercise and Diet versus Diet 
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Three trials had intervention arms that compared the combination of exercise and diet to diet 
only [33, 97, 103]. Analyses of change from baseline and post-intervention values from these 
trials revealed no statistical difference between combined exercise and diet or diet only 
interventions for any assessed primary outcome (FBG, FI, and HOMA-IR; all very low-quality 
evidence; Table 5) or secondary outcome (body weight, BMI, WC, body fat, fat-free mass, 
testosterone, SHBG and FAI; Supplementary Table 11). There were insufficient data to 
complete subgroup analyses within this comparison. 
All three trials reported a range of other outcomes not included in this meta-analysis; these are 
summarised in Supplementary Table 12.  
 
Table 5. Summary of findings for Primary Outcomes: exercise and diet versus diet. 
 
3.6 Effects of interventions: Exercise vs Diet, and Exercise and Diet vs Exercise  
Only one trial [104] compared exercise with diet, and exercise combined with diet versus 
exercise only. Effects in the diet only and combined diet and exercise group have been reported 
above and in Supplementary Table 12. The exercise only intervention reduced BMI (-0.85 
kg/m2, 95% CI: -1.69 to -0.02; P <.05), but these changes were smaller than those seen in the 
other treatment arms. Upper body fat was statistically reduced only in the exercise group (-1.57 
kg, 95% CI: -2.86 to -0.28; P <.05) and mean follicle number exhibited the greatest 
improvement in the exercise only group (P <.01). No within-group effects were reported for 
body fat (%), lower body fat (kg), lean body mass, free testosterone, insulin-like growth factor-
1, insulin-like growth factor binding protein-1, FBG, FI, HOMA-IR, LH, FSH, testosterone, 
SHBG, T/SHBG ratio, AMH, or mean ovarian volume.  
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4. DISCUSSION 
4.1 Summary of Main Results 
Our systematic review provides up-to-date evidence supporting the incorporation of exercise 
interventions in the management of PCOS. When exercise was compared with control, we 
noted statistically beneficial changes from baseline to post-intervention and more favourable 
post-intervention values for FI, TC, LDL-C, and VO2 max. Statistically positive change from 
baseline scores were also observed for HOMA-IR, triglycerides, WC, and body fat percentage, 
whereas, statistically lower post-intervention values were additionally found for BMI and 
RHR. In an analysis of a limited number of studies, compared with control, a small statistical 
effect in favour of exercise and diet was evident for WHR, but not for SHBG. In the exercise 
and diet versus diet only comparison, we found no evidence of effect in any outcome, however, 
there were strikingly scant data available.  
4.1.1 Primary Outcomes     
We found a small change in SBP from baseline to post-intervention with supervised exercise 
versus control. To our knowledge, this is the first systematic review to report on the effects of 
exercise on blood pressure in women with PCOS. Existing evidence from the general 
population suggests that aerobic exercise interventions induce the greatest improvements to 
SBP and DBP in hypertensive participants [124], with less marked effects in normotensive 
participants (small decreases in DBP and no effect on SBP). The mean SBP (116 mmHg) and 
DBP (73 mmHg) values in our review indicates that most PCOS participants were 
normotensive at baseline, thus a large effect was not anticipated.   
Regarding surrogate markers of IR, we found a statistically beneficial change (FI and HOMA-
IR) and more favourable post-intervention values (FI) with exercise compared with control. 
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Subgroup analyses also indicate that the greatest improvements are noted in participants who 
were overweight or obese and from shorter duration, supervised aerobic-based interventions. 
These findings agree with those of two previous systematic reviews, which however, did not 
make the distinction between exercise, diet or their combination, but instead compared lifestyle 
interventions to control [125, 126]. The more recent of these reviews [125] reported a small, 
but statistically significant effect on FI change (MD: -2.1 µIU/mL, 95% CI: -3.3 to -1.0; 5 
trials, I2= 0%). The other review [126] also compared the effect of lifestyle to a minimal 
treatment intervention on FI showing a statistical effect on FI post-intervention values 
favouring lifestyle (MD: -2.02 µIU/mL, 95% CI: -3.28 to -0.77; 144 participants, 5 trials, I2= 
0%). Herein, we expanded on these previous findings by incorporating a greater number of 
trials and by separating exercise only trials, thus revealing that based on the available data the 
exercise alone effects are comparable to that of lifestyle interventions.  
Although the PCOS diagnostic criteria do not currently include IR, it is widely acknowledged 
that IR plays a key role in the pathophysiology of PCOS [127]. Approximately 50-70% of 
women with PCOS have IR and hyperinsulinaemia [128], whereas many also present evidence 
of glucose intolerance [20]. Hyperinsulinaemia in PCOS further promotes secretion of 
androgens from the ovarian theca cells, whilst supressing SHBG hepatic secretion, thus 
increasing free androgens and exacerbating the associated symptoms [129]. Despite the integral 
role of IR in PCOS, there are scant FI reference values in the literature [130]. One study [131] 
reported FI levels ranging from 2-60 µIU/mL in healthy women (n= 111), with a mean value 
of 17.6±5.7 µIU/mL in women aged 25-34 years (n= 22). A large-scale case-control study of 
women with PCOS (n= 1404) reported mean FI levels of 14.3±1.6 µIU/mL, which was 
significantly higher than healthy controls [132]. The mean baseline FI level of intervention 
participants in our review was 16.21 µIU/mL, and a reduction of ~13% was reported following 
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exercise. Due to the variability of normative FI values in PCOS, it is unclear whether these 
exercise-induced reductions are clinically meaningful. 
Although FI correlates with IR, several studies, especially in normoglycemic populations [133-
134], have shown that HOMA-IR (calculated based on FI and FBG values) may be a better 
estimate of insulin sensitivity [135]. In the present review, the mean baseline HOMA-IR for 
the intervention-group participants was 2.99, which dropped to 2.43 (MD: -0.57) following 
exercise, with no evidence of reduction in the control groups. A generally adopted HOMA-IR 
cut-off value for the identification of IR is 2.6 [136]. This suggests that exercise may have a 
clinically significant effect on IR compared with usual care. Furthermore, we found no effect 
of exercise on FBG. Participants were within normal FBG at baseline, thus this combined with 
the effect on FI indicates that less insulin is needed to maintain normoglycemia following 
exercise.  
In contrast to previous reviews [126, 137], we report an effect of exercise on lipid profiles. 
Compared to control, there were improvements in exercise-induced changes for TC, LDL-C 
and triglycerides. Based on data included in our review, the mean baseline values for TC (233 
mg/dL) and LDL-C (142 mg/dL) would be classified as borderline high or even elevated in the 
presence of concomitant CVD risk factors [138]. Post-intervention values for LDL-C were 
lower for exercise compared to control, but TC levels were comparable (approximately 229 
mg/dL in both).  LDL-C appears to play a pivotal role in atherogenesis, with progressively 
increasing risk of coronary heart disease (CHD) with increasing LDL plasma levels [139]. 
Conversely, inverse associations between HDL-C and both atherosclerosis severity and CHD 
risk have been reported, with HDL-C levels ≥60 mg/dL potentially protecting against CHD 
[140]. HDL-C baseline and post-intervention values within this systematic review were >60 
mg/dL, which may partially explain why no effect of exercise was found. However, where TC 
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and LDL-C are elevated at baseline, a statistical effect is evident following exercise but the 
magnitude of the changes may not be clinically important [141, 142].  
Mean baseline triglyceride concentrations were higher in the exercise group (+11 mg/dL) 
compared with control, but both groups were within the normal range (<150 mg/dL). Exercise 
reduced triglyceride levels, but post-intervention analysis revealed that concentrations were 
still lower in the control groups. Triglycerides are independent predictors of CVD mortality in 
women [143], however, the magnitude of the observed exercise-induced triglyceride reduction, 
within the reported range, is likely to have little clinical relevance. Future research is required 
to investigate the independent effect of exercise in women with hypertriglyceridaemia. 
4.1.2 Secondary Outcomes 
We found a statistically and clinically significant effect for VO2 max (>3.5 ml/kg/min) with 
exercise compared with control. Subgroup analyses revealed that aerobic exercise, regardless 
of other variables, improved VO2 max in women with PCOS.  
Low CRF, as measured by VO2 max, has been associated with increased risk of chronic disease 
and all-cause mortality [144, 145]. Reduction in VO2 max occurs physiologically with age, but 
is also often linked to inactivity. The consequences of reduced CRF include impaired capability 
to exercise, reduced ability to perform activities of daily living, and a lower overall quality of 
life [146]. Consequently, improving patient VO2 max is a goal of many lifestyle interventions; 
yet, is often overlooked in PCOS. Studies assessing VO2 max in this patient population are 
limited; two such studies in overweight [147] and lean [148] women with PCOS reveal 
markedly lower CRF than healthy controls. The only previous relevant systematic review to 
report on VO2 max/peak [137] found improvements for both lifestyle (i.e. exercise and diet 
combined; MD: 5.09 ml/kg/min, 95% CI: 3.13 to 7.05, 3 trials, 137 participants) and exercise 
(MD: 4.86 ml/kg/min, 95% CI: 2.83 to 6.88, 2 trials, 125 participants) interventions compared 
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with usual care. Our analysis of relative VO2 max change pooled data from 92 more participants 
than the review by Haqq et al. [137], and although our effect was marginally smaller, the 
agreement between these results suggests that exercise can improve CRF in this population.   
We also found reductions in WC and body fat in the exercise groups, suggesting that exercise 
promotes favourable changes to body composition in women with PCOS. As a measure of 
central/abdominal obesity, WC is considered a better independent predictor of obesity-related 
disorders than BMI [149]. This may be attributed to the key role of central adiposity in the 
development of IR and T2DM, even in those with normal BMI [150]. However, despite 
statistical significance, the exercise-induced WC changes may be of unclear clinical relevance, 
since the observed average reduction from baseline was 2.8% (95% CI: 1.31 to 4.24), which is 
less than the suggested 3-5% reduction considered as clinically significant [151]. 
Improvements in anthropometric outcomes were reported by an older systematic review [137], 
but these were largely based on comparing lifestyle (not exercise alone) with control. Similarly, 
when compared to control, Moran et al. [126] reported statistical reductions in body weight 
and abdominal adiposity following lifestyle interventions. In our systematic review, when 
combined exercise and dietary interventions were compared with diet only, both groups 
demonstrated favourable changes, but there was no evidence of an effect favouring either 
intervention for any outcome. 
We found no statistical effect of exercise on the androgenic profile of women with PCOS 
compared with control. Where analyses were possible, we found no effect favouring either diet 
and exercise combined or diet only. This was further supported by subgroup analyses where 
the evidence of relevant effects was minimal. Typically, the baseline values of women with 
PCOS included in this current review were below recommended cut-offs for diagnosing 
hyperandrogenism; testosterone >2.5 nmol/L and SHBG <30 nmol/L [152], which indicates 
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that they were not markedly hyperandrogenic. Moran et al. [126] reported reduced testosterone 
levels following lifestyle intervention but found no effect on FAI (100 x total 
testosterone/SHBG), a more valid marker of hyperandrogenism [121]. A review of exercise-
induced changes on the androgenic profile of healthy women who were premenopausal [153] 
found that exercise acutely increases circulating androgens, but the chronic effects are less 
clear. A similar meta-analysis [154] reported a chronic statistical reduction in concentrations 
of bioavailable testosterone (MD: -0.18 pg/mL, 95% CI: -0.29 to -0.07; 1369 participants, 9 
trials, I2= 0%) and increased SHBG (MD: 3.93 nmol/L, 95% CI: 0.98 to 6.87; 1643 participants, 
14 trials, I2= 75%) following exercise in healthy women. Collectively, these data suggest that 
exercise interventions may regulate androgenic profiles, but that the optimal dose is unclear, 
with potential variation in women with menstrual disruption [155]. 
Finally, there is increasing recognition of the deleterious effects of PCOS on HRQoL and other 
psychosocial components. However, only three eligible trials measured these outcomes in the 
exercise versus control comparison. There was no evidence of effect in any of the PCOS-Q 
domains, but scores were improved in the physical functioning, general health, social 
functioning and mental health domains of the SF-36. Our meta-analysis revealed improvements 
in these outcomes of ≥10% for exercise compared with control, supporting the notion that 
exercise in these patients may improve their perception of physical and mental wellbeing. 
 
4.2 Overall completeness and applicability of evidence 
We completed a comprehensive and systematic search of relevant electronic databases, and the 
reference lists from included publications and relevant reviews. From this we identified 16 
RCTs, one quasi-RCT, and a randomised crossover trial. We located and meta-analysed data 
from more trials, made a greater number of comparisons and included a wider range of 
38 
 
outcomes when compared to previous systematic reviews [25, 125-126, 148]. To our 
knowledge, it is the first time data from 10 of the trials included in this systematic review have 
been meta-analysed [32, 34, 101, 103, 107-107, 109-110, 117, 119] suggesting that this is the 
most comprehensive and up-to-date systematic review on the topic of exercise in the treatment 
of women with PCOS.  
However, there are limitations to this systematic review. It is likely that many of the included 
trials were not sufficiently powered to detect meaningful differences between test groups. 
Indeed, only seven included trials state the methods used to calculate sample size, and due to 
small participant numbers (e.g. median: exercise n= 11; control n= 12) it is unlikely that 
sufficient statistical power was achieved to either make the findings generalisable into the 
population, or to ensure that false positive/negative results were not reported. Therefore, it is 
important that future trials are sufficiently powered to detect changes in their primary 
outcomes. 
PCOS is a heterogeneous condition and can exhibit phenotypes with varying levels of 
underlying hyperandrogenism, menstrual disorders and polycystic ovarian morphology [156]. 
It is likely that different phenotypes may respond differently to exercise and/or dietary 
interventions. Most included trials did not target a specific PCOS phenotype, and our protocol 
included a PCOS diagnosis based on any of the existing PCOS definitions/criteria. Future work 
should focus on PCOS subgroups/phenotypes and investigate the exercise-induced effects 
accordingly. Another concern surrounds the representativeness of the populations included in 
the review; it is not clear whether the ethnicity, socio-economic or educational status of 
participants is representative of the typical patient or to what degree these variables may have 
influenced the observed effects.   
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All included trials reported baseline and immediately post-intervention data; only one trial 
[111] completed follow-up beyond the end of the intervention. Consequently, the lasting, long-
term effect of exercise for women with PCOS is unknown. Future research is needed to 
determine whether behaviours relating to PA are changed in this patient population due to 
exercise interventions, and whether the noted physiological effects remain beyond the short-
term.  
 
4.3 Quality of the evidence 
Due to the nature of the interventions, all included trials were judged to have a high risk of 
performance bias. All but one trial was judged to have a high detection bias risk due to lack of 
blinding outcome assessors and, although logistically difficult, steps could have been taken to 
minimise this bias in each trial. Selection and reporting bias were inadequately reported in 
>50% of trials so a judgement of unclear risk was made and nearly 45% of the included trials 
(n= 8) were judged to be at a high risk of attrition bias. Six trials were at an unclear or high risk 
of baseline group imbalance, whereas, adherence and contamination were generally unreported 
resulting in an unclear judgement. Disappointingly few studies reported adherence data (33%, 
n= 6), but of the trials that did report these data, adherence rates were generally good (median: 
90%). Similarly, in the 10 trials reporting attrition, the median value was 19.5%; five of these 
were under the 20% attrition threshold outlined in the protocol. 
Statistical effects were reported in 13 of the main analyses; in three of those, there was evidence 
of at least substantial heterogeneity (I2 ≥50%), but this was largely explained by subgroups 
and/or removal of trials with the most extreme values. For our primary outcomes, the quality 
of evidence was rated as very low to low due to a combination of unclear or high risk 
randomisation or allocation procedures, lack of blinding, unclear or improper handling of 
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missing data, high attrition, unclear risk of selective reporting bias, contamination, low 
adherence, or considerable heterogeneity. We downgraded all outcomes because of 
imprecision resulting from small number of participants and either wide confidence intervals 
for the effect estimate, or the null effect, as well as an appreciable benefit was included in the 
confidence interval for the mean difference.  
 
4.4 Limitations and potential biases in the review process 
In addition to the limitations mentioned in section 4.2., there are also further possible 
limitations to this systematic review. Despite a thorough and comprehensive search of relevant 
databases, we may have missed trials that would have been eligible for inclusion. Additionally, 
we did not identify any additional studies from the reference lists of the included publications; 
although this may support the comprehensiveness of our searches, it may also represent a 
methodological error. Also, no language restriction in our searches meant several foreign 
language papers were returned; three trials in Persian [103, 109-110], and one in Hungarian 
[106]. To assess these trials, translation services and software were required, and whilst 
interpretation of results tables was straightforward, evaluation of methodological quality was 
more challenging. Consequently, when assessing risk of bias in these trials, judgements of 
‘unclear risk’ had to be made. 
Finally, only full publications were eligible for inclusion and this could contribute to 
publication bias. Although, including grey literature may have influenced the findings of this 
review, it may have also increased the risk of associated bias. Unfortunately, due to a lack of 
eligible trials, publication bias analysis was not performed.  
4.5 Future Directions 
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Based upon our findings, it is apparent that there is a lack of trials that compare exercise and 
diet combined with other comparators, such as diet only, exercise only, or a standard treatment 
control. Considering that lifestyle changes (i.e. diet and exercise) are recommended in the 
management of PCOS, studies assessing the effectiveness of these interventions are scarce and 
the available data are not sufficient to lead to definite conclusions/recommendations for the 
clinical practice. Future trials should aim to make comprehensive comparisons involving 
interventions that incorporate both exercise and diet.  
Furthermore, the eligible studies included in the current systematic review generally have small 
sample sizes, whilst even those studies that have reported power calculations appear under-
powered to detect meaningful changes in all reported outcomes. Therefore, it is important that 
future studies are robustly designed and sufficiently powered to better inform future clinical 
practice guidelines/recommendations. Considering the high prevalence of PCOS in 
reproductive-aged women, large RCTs studying the effectiveness of lifestyle interventions in 
this young patient population are still clearly needed. 
We also identified a lack of follow-up testing beyond the intervention period to assess the 
longer-term effects of such lifestyle interventions. Without follow-up reassessments, it is 
impossible to determine whether any intervention-induced improvements are maintained, and 
if the applied intervention has resulted in sustained changes in lifestyle behaviours of 
participants, an aspect which is vital for the long-term management of these patients. 
 
5. Conclusion 
When data were pooled in a meta-analysis, changes from baseline statistically favoured 
exercise over control for FI, HOMA-IR, TC, LDL-C, triglycerides, VO2 max, WC, and body 
fat percentage. Furthermore, a comparison of immediately post-intervention values also 
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revealed statistical effects on FI, TC, LDL-C, VO2 max, RHR, and BMI. Compared with 
control, exercise also improved the physical functioning, general health, social functioning, 
and mental health domains assessed in the SF-36. Subgroup analyses revealed that the greatest 
favourable changes with exercise versus control were seen in participants who were either 
overweight (FI, HOMA-IR, triglycerides, VO2 max and WC) or obese (BMI, body mass and 
WC). Post-intervention value analyses also showed beneficial effects in those who were 
overweight (LDL-C, VO2 max, RHR, BMI, WC and body fat percentage). Aerobic exercise 
interventions improved FI, HOMA-IR, TC, triglycerides, VO2 max, BMI, WC and body fat 
percentage. In contrast, resistance training lowered HDL-C concentrations and increased BMI, 
but reduced WC; post-intervention improvements in HDL-C were also apparent following 
resistance exercise. Supervised exercise interventions improved outcomes more than 
unsupervised interventions compared with control. Shorter duration interventions performed 
better than longer interventions; improved change from baseline FI, HOMA-IR, TC, LDL-C, 
triglycerides, VO2 max and WC was found in shorter duration trials, compared with only 
improved VO2 max in those >12 weeks. Based on limited available data, we found no 
differences between the effects of exercise and diet combined, and diet alone. Due to lack of 
available trials, it was not possible to compare the effectiveness of exercise versus diet or 
exercise and diet combined versus diet. 
Although the evidence presented within this systematic review has largely been drawn from 
RCTs, a cautious approach should be adopted when interpreting the findings. Many of the 
outcomes presented modest effects and wide confidence intervals (indicating greater 
uncertainty). Furthermore, we found the statistical effects in many of the analyses to be 
sensitive to the addition or removal of individual trials regardless of their weighting within the 
analysis. Using the GRADE approach, we rated the quality of evidence as very low or low for 
all primary outcomes. Future trials should be rigorously designed and sufficiently powered so 
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that they are more generalizable to the wider PCOS population. In order to be more closely 
aligned with current treatment recommendations, future studies should ideally include a dietary 
component alongside exercise interventions. 
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Additional Files  
Additional data and analyses are provided in Additional Files 1, 2, 3 and 4. 
File name: Additional File 1.pdf 
Title of Data: Supplementary Tables 
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Description of Data: Supplementary Table 1: Search algorithm; Supplementary Table 2: Review 
authors’ judgment on risk of bias; Supplementary Table 3: Details of excluded studies and reasons for 
exclusion; Supplementary Table 4: Diagnostic criteria/definition applied for PCOS; Supplementary 
Table 5: Effect estimates and heterogeneity from sub-group analyses in blood pressure and metabolism-
related outcomes; Supplementary Table 6: Effect estimates and heterogeneity from sub-group analyses 
in lipid-related outcomes; Supplementary Table 7: Effect estimates and heterogeneity from sub-group 
analyses in cardiorespiratory, anthropometric and body composition related outcomes; Supplementary 
Table 8: Effect estimates and heterogeneity from sub-group analyses in androgenic and inflammatory 
outcomes; Supplementary Table 9: Exercise vs control - Summary of findings from investigative 
outcomes that were only reported in single trials; Supplementary Table 10: Exercise and Diet vs Control 
- Summary of findings from investigative outcomes that were only reported in single trials; 
Supplementary Table 11: Effect estimates and heterogeneity for change from baseline to immediately 
post-intervention, and immediately post-intervention values only, for all outcomes analysed in the 
comparison Exercise and Diet versus Diet Only; Supplementary Table 12: Exercise and Diet vs Diet - 
Summary of findings from investigative outcomes that were only reported in single trials. 
 
File name: Additional File 2.pdf 
Title of Data: Supplementary Figures 
Description of Data: Supplementary Figure 1: Review of authors' judgements about each risk of bias 
item for each included study; Supplementary Figure 2: Forest plot of comparison: Exercise vs. Control. 
Analysis of immediately post-intervention values for outcomes related to participant lipid profile; 
Supplementary Figure 3: Forest plot of comparison: Exercise vs. Control. Analysis of resting heart rate 
sub-groups by intervention type; Supplementary Figure 4: Forest plot of comparison: Exercise vs. 
Control, change from baseline; Outcome: SF-36 Domains; Supplementary Figure 5: Forest plot of 
comparison: Exercise and Diet vs. Control; outcome: Waist to Hip Ratio; Supplementary Figure 6: 
Forest plot of comparison: Exercise and Diet vs. Control, change from baseline. Outcome: SHBG. 
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File name: Additional File 3.pdf 
Title of Data: PRISMA Checklist 
 
File name: Additional File 4.pdf 
Title of Data: Additional meta-analyses/complete dataset 
Description of Data: Supplementary Meta-Analyses: Exercise versus Control; Exercise and Diet 
versus Diet 
